Subtopic Deep Dive
Kidney Transplantation Outcomes
Research Guide
What is Kidney Transplantation Outcomes?
Kidney Transplantation Outcomes analyzes graft survival rates, rejection incidence, patient longevity, and comparative effectiveness against dialysis using large-scale registry data.
Studies quantify five-year graft survival from living unrelated donors matching parental donors despite HLA mismatch (Terasaki et al., 1995, 1220 citations). Marginal cadaveric donor kidneys yield superior survival versus wait-listed dialysis patients (Ojo et al., 2001, 871 citations). Desensitization protocols enable HLA-incompatible transplants with doubled eight-year survival benefits over waiting lists (Montgomery et al., 2011, 660 citations). Over 20 papers from 1955-2015 form the core literature base.
Why It Matters
Superior graft survival data from marginal donors justifies expanded criteria, increasing transplant volumes by prioritizing kidneys over dialysis (Ojo et al., 2001; Metzger et al., 2003). Desensitization outcomes support policy shifts toward incompatible living donors, reducing waitlist mortality for sensitized patients (Montgomery et al., 2011). Long-term analyses reveal stagnant half-lives post-1995, guiding immunosuppression refinements and allocation reforms (Meier-Kriesche et al., 2004). Registry reports like OPTN/SRTR 2013 inform annual policy adjustments (Matas et al., 2015).
Key Research Challenges
Marginal Donor Viability Assessment
Defining expanded criteria for cadaveric donors balances supply gains against reduced graft longevity. Ojo et al. (2001) show marginal kidneys outperform dialysis but trail ideal donors. Metzger et al. (2003) highlight additive risks from donor age and comorbidities.
Immunosuppression Long-term Toxicity
Calcineurin inhibitors cause chronic renal failure in 7-21% of nonrenal transplant recipients within five years. Ojo et al. (2003) link this to allograft nephropathy. Meier-Kriesche et al. (2004) report no half-life gains since 1995 despite regimen tweaks.
HLA-Incompatible Desensitization Risks
Plasmapheresis and IVIG protocols enable transplants but face antibody rebound challenges. Montgomery et al. (2011) demonstrate survival edges yet note infection vulnerabilities. Racial access disparities persist despite preferences (Ayanian et al., 1999).
Essential Papers
Chronic Renal Failure after Transplantation of a Nonrenal Organ
Akinlolu Ojo, Philip J. Held, Friedrich K. Port et al. · 2003 · New England Journal of Medicine · 2.2K citations
The five-year risk of chronic renal failure after transplantation of a nonrenal organ ranges from 7 to 21 percent, depending on the type of organ transplanted. The occurrence of chronic renal failu...
High Survival Rates of Kidney Transplants from Spousal and Living Unrelated Donors
Paul I. Terasaki, J. Michael Cecka, David W. Gjertson et al. · 1995 · New England Journal of Medicine · 1.2K citations
Spouses are an important source of living-donor kidney grafts because, despite poor HLA matching, the graft-survival rate is similar to that of parental-donor kidneys. This high rate of survival is...
Survival in Recipients of Marginal Cadaveric Donor Kidneys Compared with Other Recipients and Wait-Listed Transplant Candidates
Akinlolu Ojo, Julie A. Hanson, Herwig‐Ulf Meier‐Kriesche et al. · 2001 · Journal of the American Society of Nephrology · 871 citations
Abstract. An increasing number of cadaveric kidney transplants are now performed with organs from donors who would have been deemed unsuitable in earlier times. Although good allograft outcomes hav...
Expanded criteria donors for kidney transplantation
Robert A. Metzger, Francis L. Delmonico, Sandy Feng et al. · 2003 · American Journal of Transplantation · 667 citations
The ideal deceased organ donor is a younger person who dies from traumatic head injury that is isolated to the brain and leaves the thoracic and abdominal organ function intact. Such a deceased don...
Desensitization in HLA-Incompatible Kidney Recipients and Survival
Robert A. Montgomery, Bonnie E. Lonze, Karen E. King et al. · 2011 · New England Journal of Medicine · 660 citations
Live-donor transplantation after desensitization provided a significant survival benefit for patients with HLA sensitization, as compared with waiting for a compatible organ. By 8 years, this survi...
The utility of marginal donors in liver transplantation
R. Busuttil, Koichi Tanaka · 2003 · Liver Transplantation · 656 citations
The shortage of organs has led centers to expand their criteria for the acceptance of marginal donors. The combination of multiple marginal factors seems to be additive on graft injury. In this rev...
EXPERIENCES WITH RENAL HOMOTRANSPLANTATION IN THE HUMAN: REPORT OF NINE CASES 1
David M. Hume, John P. Merrill, Benjamin F. Miller et al. · 1955 · Journal of Clinical Investigation · 622 citations
Reading Guide
Foundational Papers
Start with Terasaki et al. (1995) for living donor survival benchmarks, then Ojo et al. (2001) for marginal cadaveric comparisons, as they establish core metrics against dialysis.
Recent Advances
Montgomery et al. (2011) for desensitization survival gains; Matas et al. (2015) OPTN/SRTR for 2013 registry benchmarks.
Core Methods
Kaplan-Meier survival analysis, Cox proportional hazards from registries; desensitization via plasmapheresis/IVIG; expanded criteria donor scoring.
How PapersFlow Helps You Research Kidney Transplantation Outcomes
Discover & Search
Research Agent uses searchPapers to retrieve all 250M+ OpenAlex papers on 'kidney graft survival marginal donors', then citationGraph on Ojo et al. (2001, 871 citations) reveals forward citations like Metzger et al. (2003), while findSimilarPapers expands to living donor outcomes (Terasaki et al., 1995). exaSearch queries 'desensitization HLA incompatible kidney survival' for Montgomery et al. (2011).
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival curves from Ojo et al. (2001), then runPythonAnalysis with pandas fits Kaplan-Meier models to registry data for GRADE A evidence grading. verifyResponse (CoVe) cross-checks claims like 8-year survival doubling in Montgomery et al. (2011) against OPTN/SRTR 2013 (Matas et al., 2015) for statistical verification.
Synthesize & Write
Synthesis Agent detects gaps in long-term marginal donor data post-2003 via contradiction flagging between Ojo et al. (2001) and Meier-Kriesche et al. (2004), then Writing Agent uses latexEditText for outcome tables, latexSyncCitations to integrate 10 papers, and latexCompile for publication-ready review. exportMermaid generates survival flowchart diagrams.
Use Cases
"Run survival analysis on marginal donor kidney data from Ojo 2001 vs dialysis."
Research Agent → searchPapers('marginal cadaveric kidney survival') → Analysis Agent → readPaperContent(Ojo et al. 2001) → runPythonAnalysis(pandas Kaplan-Meier fit, matplotlib curves) → researcher gets CSV-exported hazard ratios and p-values.
"Write LaTeX review on desensitization outcomes with citations."
Synthesis Agent → gap detection(HLA incompatible) → Writing Agent → latexEditText(draft) → latexSyncCitations(Montgomery 2011, Terasaki 1995) → latexCompile → researcher gets PDF manuscript with synced bibliography.
"Find GitHub repos analyzing OPTN kidney transplant data."
Research Agent → searchPapers('OPTN/SRTR kidney') → paperExtractUrls(Matas 2015) → paperFindGithubRepo → githubRepoInspect → researcher gets repo code for survival modeling replication.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ papers on graft survival, chaining searchPapers → citationGraph → DeepScan 7-step verification with CoVe checkpoints on Ojo et al. (2003) renal failure risks. Theorizer generates hypotheses on immunosuppression from Meier-Kriesche et al. (2004) half-life stagnation, exporting Mermaid theory diagrams. DeepScan analyzes racial disparities in Ayanian et al. (1999) with runPythonAnalysis on access metrics.
Frequently Asked Questions
What defines kidney transplantation outcomes?
Graft survival, rejection rates, and patient survival versus dialysis, measured via registry data like OPTN/SRTR.
What methods assess marginal donor kidneys?
Expanded criteria using donor age, creatinine, and hypertension; survival compared to wait-listed candidates (Ojo et al., 2001; Metzger et al., 2003).
What are key papers?
Ojo et al. (2003, 2179 citations) on post-transplant renal failure; Terasaki et al. (1995, 1220 citations) on living unrelated donors; Montgomery et al. (2011, 660 citations) on desensitization.
What open problems exist?
Stagnant long-term allograft half-lives since 1995 (Meier-Kriesche et al., 2004); optimizing immunosuppression to curb chronic allograft nephropathy.
Research Organ Donation and Transplantation with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Kidney Transplantation Outcomes with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers